Royalty Pharma plc Files 8-K on Executive Changes and Financials
Ticker: RPRX · Form: 8-K · Filed: Jul 17, 2025 · CIK: 1802768
| Field | Detail |
|---|---|
| Company | Royalty Pharma PLC (RPRX) |
| Form Type | 8-K |
| Filed Date | Jul 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-changes, financial-reporting
TL;DR
Royalty Pharma 8-K: Exec changes, director elections, and financials filed July 17, 2025.
AI Summary
Royalty Pharma plc filed an 8-K on July 17, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits. The company is incorporated in England and Wales and its principal executive offices are located at 110 East 59th Street, New York, NY.
Why It Matters
This filing provides updates on the company's leadership and financial reporting, which are crucial for investors to understand the current governance and financial health of Royalty Pharma plc.
Risk Assessment
Risk Level: low — This is a routine filing reporting on corporate governance and financial statements, not indicating any immediate operational or financial distress.
Key Numbers
- 001-39329 — SEC File Number (Identifies the company's filing history with the SEC.)
- 98-1535773 — I.R.S. Identification No. (Company's tax identification number.)
Key Players & Entities
- Royalty Pharma plc (company) — Registrant
- July 17, 2025 (date) — Date of earliest event reported
- England and Wales (jurisdiction) — State or other jurisdiction of incorporation
- 110 East 59th Street, New York, New York 10022 (address) — Address of principal executive offices
FAQ
What specific executive or director changes are being reported in this 8-K?
The filing indicates reporting on the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' but does not detail the specific individuals or changes within this summary.
What type of financial statements are included in this filing?
The filing states 'Financial Statements and Exhibits' are included, but the specific nature or period covered by these statements is not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated July 17, 2025.
Where are Royalty Pharma plc's principal executive offices located?
Royalty Pharma plc's principal executive offices are located at 110 East 59th Street, New York, New York 10022.
What is the company's SIC code?
The Standard Industrial Classification (SIC) code for Royalty Pharma plc is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 17, 2025 regarding Royalty Pharma plc (RPRX).